# US 6,410,033 B1 · Recombinant infectious bovine rhinotracheitis virus > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 6,410,033 B1 - Document ID: US6410033B1 - Status: Granted - Kind: B1 - Application number: 08/379,647 - Filed: 1996-08-05 - Granted: 2002-06-25 - Earliest claimed: 1987-07-27 - Assignees: Syntro Corporation - Inventors: Mark D. Cochran - Web page: https://patentgrep.com/patent/US6410033B1 ## CPC - A61K 39/265: Infectious rhinotracheitis virus - A61K 39/12: Viral antigens - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - C12N 15/86: Viral vectors - A61K 2039/5252: {inactivated (killed)} - A61K 2039/5256: {expressing foreign proteins} - A61K 2039/552: {Veterinary vaccine} - A61K 2039/70: {Multivalent vaccine} - C12N 2710/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N 2710/16043: viral genome or elements thereof as genetic vector - C12N 2710/16721: Viruses as such, e.g. new isolates, mutants or their genomic sequences - C12N 2710/16734: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein - C12N 2710/16743: viral genome or elements thereof as genetic vector - C12N 2710/16762: by genetic engineering - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention provides a recombinant infectious bovine rhinotracheitis designated S-IBR-052 (ATCC Accession No. VR 2443). The present invention also provides a vaccine which comprises an effective immunizing amount of the recombinant infectious bovine rhinotracheitis virus designated S-IBR-052 and a suitable carrier. The present invention provides homology vectors, methods of immunization and a method of distinguishing an animal vaccinated with the vaccines of the present invention from an animal infected with a naturally-occurring infectious bovine rhinotracheitis virus. ## Claims ### Claim 1 A recombinant infectious bovine rhinotracheitis virus comprising a foreign DNA sequence inserted into an infectious bovine rhinotracheitis viral genome, wherein the foreign DNA sequence is inserted within the BamHI C fragment of the infectious bovine rhinotracheitis viral genome and is capable of being expressed in an infectious bovine rhinotracheitis virus infected host cell. ### Claim 2 (depends on 1) The recombinant infectious bovine rhinotracheitis virus of claim 1, wherein the foreign DNA sequence is inserted within the largest BamHI-KpnI subfragment of the BamHI C fragment of the infectious bovine rhinotracheitis viral genome. ### Claim 3 (depends on 2) The recombinant infectious bovine rhinotracheitis virus of claim 2, wherein the foreign DNA sequence is inserted within a HindIII site located within the largest BamHI-KpnI subfragment of the infectious bovine rhinotracheitis viral genome. ### Claim 4 (depends on 2) The recombinant infectious bovine rhinotracheitis virus of claim 2, wherein the foreign DNA sequence is inserted within an XbaI site located within the largest BamHI-KpnI subfragment of the infectious bovine rhinotracheitis viral genome. ### Claim 5 (depends on 1) The recombinant infectious bovine rhinotracheitis virus of claim 1, wherein the foreign DNA sequence is inserted within the smallest KpnI-BamHI subfragment of the BamHI C fragment of the infectious bovine rhinotracheitis viral genome. ### Claim 6 (depends on 5) The recombinant infectious bovine rhinotracheitis virus of claim 5, wherein the foreign DNA sequence is inserted within an EcoRV site located within the smallest KpnI-BamHI subfragment of the infectious bovine rhinotracheitis viral genome. ### Claim 7 (depends on 1) The recombinant infectious bovine rhinotracheitis virus of claim 1, further comprising a deletion in a non-essential region of the infectious bovine rhinotracheitis viral genome. ### Claim 8 (depends on 7) The recombinant infectious bovine rhinotracheitis virus of claim 7, wherein the deletion is in a US2 gene, a gG gene or a gE gene region. ### Claim 9 (depends on 1) The recombinant infectious bovine rhinotracheitis virus of claim 1, wherein the foreign DNA sequence encodes a polypeptide. ### Claim 10 (depends on 9) The recombinant infectious bovine rhinotracheitis virus of claim 9, wherein the polypeptide is antigenic in an animal into which the recombinant infectious bovine rhinotracheitis virus is introduced. ### Claim 11 (depends on 9) The recombinant infectious bovine rhinotracheitis virus of claim 9, wherein the polypeptide is E. coli beta-galactosidase. ### Claim 12 (depends on 1) The recombinant infectious bovine rhinotracheitis virus of claim 1, wherein the foreign DNA sequence encodes a cytokine or cytokine receptor. ### Claim 13 (depends on 12) The recombinant infectious bovine rhinotracheitis virus of claim 12, wherein the cytokine or cytokine receptor is selected from the group consisting of: chicken myelomonocytic growth factor (cMGF), chicken interferon (cIFN), interleukin-2, interleukin-6, interleukin-12, interferons, granulocyte-macrophage colony stimulating factors, transforming growth factor beta, epidermal growth factors, fibroblast growth factors, hepatocyte growth factor, insulin-like growth factors, B-nerve growth factor, platelet-derived growth factor, vascular endothelial growth factor, interleukin 1, IL-1 receptor antagonist, interleukin 3, interleukin 4, interleukin 5, IL-6 soluble receptor, interleukin 7, interleukin 8, interleukin 9, interleukin 10, interleukin 11, interleukin 13, angiogenin, chemokines, colony stimulating factors, erythropoietin, interferon gamma, leukemia inhibitory factor, oncostatin M, pleiotrophin, secretory leukocyte protease inhibitor, stem cell factor, tumor necrosis factors, soluble TNF receptors and interleukin receptors. ### Claim 14 (depends on 10) The recombinant infectious bovine rhinotracheitis virus of claim 10, wherein the antigenic polypeptide is an equine influenza virus neuroaminidase or an equine influenza virus hemagglutinin. ### Claim 15 (depends on 10) The recombinant infectious bovine rhinotracheiti virus of claim 10, wherein the antigenic polypeptide is selected from the group consisting of equine influenza virus type A/Alaska 91 neuraminidase, equine influenza virus type A/Alaska 91 hemagglutinin, equine influenza virus type A/Prague 56 neuraminidase, equine influenza virus type A/Prague 56 hemagglutinin, equine influenza virus type A/Miami 63 neuraminidase, equine influenza virus type A/Miami 63 hemagglutinin, equine influenza virus type A/Kentucky 81 neuraminidase equine influenza virus type A/Kentucky 81 hemagglutinin, equine herpesvirus type 1 glycoprotein B, and equine herpesvirus type 1 glycoprotein D. ### Claim 16 (depends on 10) The recombinant infectious bovine rhinotracheitis virus of claim 10, wherein the antigenic polypeptide is selected from the group consisting of hog cholera virus gE1, hog cholera virus gE2, swine influenza virus hemagglutinin, neuraminidase, matrix protein, nucleoprotein, pseudorabies virus gB, pseudorabies virus gC, pseudorabies virus gD, and PRRS virus ORF7. ### Claim 17 (depends on 10) The recombinant infectious bovine rhinotracheitis virus of claim 10, wherein the antigenic polypeptide is selected from the group consisting of: bovine respiratory syncytial virus attachment protein (BRSV G), bovine respiratory syncytial virus fusion protein (BRSV F), bovine respiratory syncytial virus nucleocapsid protein (BRSV N), bovine coronavirus, bovine rotavirus glycoprotein 38, bovine parainfluenza virus type 3 fusion protein, and bovine parainfluenza virus type 3 hemagglutinin neuraminidase. ### Claim 18 (depends on 10) The recombinant infectious bovine rhinotracheitis virus of claim 10, wherein the antigenic polypeptide is bovine viral diarrhea virus (BVDV) glycoprotein 48 or bovine viral diarrhea virus (BVDV) glycoprotein 53. ### Claim 19 (depends on 10) The recombinant infectious bovine rhinotracheitis virus of claim 10, wherein the antigenic polypeptide is selected from the group consisting of Marek's disease virus gA, Marek's disease virus gB, Marek's disease virus gD, Newcastle disease virus HN, Newcastle disease virus F, infectious laryngotracheitis virus gB, infectious laryngotracheitis virus gI, infectious laryngotracheitis virus gD, infectious bursal disease virus VP2, infectious bursal disease virus VP3, infectious bursal disease virus VP4, infectious bursal disease virus polyprotein, infectious bronchitis virus spike, infectious bronchitis virus matrix and chick anemia virus matrix. ### Claim 20 (depends on 1) The recombinant infectious bovine rhinotracheitis virus of claim 1, wherein the foreign DNA sequence is under the control of an endogenous infectious bovine rhinotracheitis virus promoter. ### Claim 21 (depends on 20) The recombinant infectious bovine rhinotracheitis virus of claim 20, wherein the foreign DNA sequence is under the control of a heterologous herpesvirus promoter. ### Claim 22 (depends on 21) The recombinant infectious bovine rhinotracheitis virus of claim 21, wherein the promoter is selected from the group consisting of a herpes simplex virus type 1 (HSV-1) ICP4 protein promoter, an HSV-1 TK promoter, a pseudorabies virus (PRV) glycoprotein X promoter, a PRV gX promoter, an HCMV immediate early promoter, a Marek's disease virus gA promoter, a Marek's disease virus gB promoter, a Marek's disease virus gD promoter, an infectious laryngotracheitis virus gB promoter, a BHV-1.1 VP8 promoter and an infectious laryngotracheitis virus gD promoter. ### Claim 23 (depends on 1) A vaccine which comprises an effective immunizing amount of the recombinant infectious bovine rhinotracheitis virus of claim 1 and a carrier. ### Claim 24 (depends on 23) The vaccine of claim 23, wherein the carrier is a physiologically balanced culture medium containing stabilizing agents. ### Claim 25 (depends on 23) The vaccine of claim 23, wherein the effective immunizing amount is from about 103 to about 108 PFU/dose. ### Claim 26 (depends on 25) The vaccine of claim 25, wherein the effective immunizing amount is from about 104 to about 107 PFU/dose. ### Claim 27 (depends on 25) The vaccine of claim 25, wherein the effective immunizing amount is from about 104 to about 106 PFU/dose. ### Claim 28 (depends on 23) A method of immunizing an animal against disease caused by infectious bovine rhinotracheitis virus which comprises administering to the animal an effective immunizing dose of the vaccine of claim 23. ### Claim 29 (depends on 10) The recombinant infectious bovine rhinotracheitis virus of claim 10, wherein the antigenic polypeptide is from an organism or virus selected from the group consisting of Streptococcus equi, equine infectious anemia virus, equine encephalitis virus, equine rhinovirus and equine rotavirus. ### Claim 30 (depends on 10) The recombinant infectious bovine rhinotracheitis virus of claim 10, wherein the antigenic polypeptide is from an organism or virus selected from the group consisting of avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian influenza virus, avian adenovirus, fowlpox virus, avian coronavirus, avian rotavirus, chick anemia virus, Salmonella spp., E. coli, Pasteurella spp., Bordetella spp., Eimeria spp., Histomonas spp., Trichomonas spp., poultry nematodes, cestodes, trematodes, poultry mites, poultry lice and poultry protozoa.